Histoplasmosis Relapse Rates Found Low in Study
Immunocompromised patients showed low relapse rates even when antifungal therapy was ended early.
Updated on Sept. 23, 2026 in Diseases — General
A study published on September 12, 2026, found that relapse occurred in 6.6% of immunocompromised patients who discontinued antifungal therapy before 12 months. The research followed 106 adults diagnosed with histoplasmosis between 2005 and 2025.
Why it matters
This research provides clinical insights into the safety of shortening antifungal treatment durations for immunocompromised patients, offering potential alternatives to standard long-term therapy guidelines.
The study analyzed 106 immunocompromised patients, finding that while relapse was low at 6.6%, shorter treatment duration correlated with a 3.64 odds ratio for all-cause rehospitalization. Median follow-up lasted 1411 days for the short-duration group.
The players
Indiana University School of Medicine
This academic medical center served as the lead research institution for the study on histoplasmosis treatment.
The details
Researchers at the Indiana University School of Medicine assessed clinical outcomes following therapy discontinuation in immunocompromised adults. While the infection-related death rate was zero, patients who received less than 12 months of antifungal treatment experienced higher rates of rehospitalization.
Timeline
The study tracked patients diagnosed between 2005 and 2025.
Findings were published on September 12, 2026.
The Big Picture
This research expands upon the Indiana University School of Medicine clinical research guidelines by providing long-term outcome data for immunocompromised patients. It marks a departure from traditional treatment timelines by investigating the safety of ending therapy prior to the 12-month mark.
Patients should discuss the results of this study with their infectious disease specialist to determine if shorter antifungal regimens are appropriate for their specific case. Understanding the link between shorter treatment and rehospitalization rates is critical for managing personal health routines.
The takeaway
Clinicians and patients can use this data to better balance the risks of relapse against the burdens of long-term antifungal therapy. Early discontinuation should be carefully weighed against the observed increase in all-cause rehospitalization rates.
Further reading
For more information on current treatment standards, visit the Diseases — General section.
Source note: This article includes information reported by Medscape.
